Teva has filed an NDA with the FDA for ecopipam in pediatric Tourette syndrome, supported by Phase 3 data showing delayed relapse versus placebo. If approved, it would be the first novel D1 receptor therapy for this population in over a decade.
Written By: Umesh Hanumante,
M.Pharm (Reg. Affairs)
Reviewed By: Pharmacally Editorial Team
Teva has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking approval of ecopipam for the treatment of pediatric Tourette syndrome. The filing is supported by positive Phase 3 data published in JAMA Neurology, where the investigational therapy significantly delayed relapse compared with placebo in children and adolescents who responded to treatment.
If approved, ecopipam could become the first FDA-approved therapy with a novel mechanism of action for pediatric Tourette syndrome in more than ten years. The drug has already received FDA Orphan Drug and Fast Track designations, reflecting the significant unmet need in this patient population.
Scientific and Clinical Context
Tourette syndrome is a chronic neurodevelopmental disorder characterized by involuntary motor and vocal tics that typically emerge between 5 and 10 years of age. Symptoms can interfere with daily functioning, social interactions, and academic performance. Although several treatment options exist, many patients experience limited symptom control or treatment-related adverse effects, creating demand for safer and more effective therapies.
Ecopipam introduces a different therapeutic approach by selectively blocking dopamine signaling through the D1 receptor. Unlike currently available therapies that primarily target D2 receptors, ecopipam addresses a distinct pathway believed to contribute to the repetitive and compulsive behaviors associated with Tourette syndrome.
Phase 3 Trial Results
The NDA submission is based on results from a Phase 3 relapse-prevention study (NCT05615220) evaluating ecopipam in pediatric patients with Tourette syndrome. The trial enrolled patients who achieved a stable clinical response during an open-label treatment period and subsequently randomized them to continue ecopipam or switch to placebo.
The primary endpoint measured time to relapse using the Yale Global Tic Severity Scale Total Tic Score (YGTSS-TTS). Patients receiving ecopipam experienced a significantly longer time to relapse compared with placebo, meeting the primary endpoint with statistical significance (p=0.008).
The safety profile was generally favorable and consistent with previous studies. The most common treatment-related adverse events included somnolence (11.1%), anxiety (9.7%), headache (9.7%), insomnia (8.8%), tic worsening (7.9%), and fatigue (6.5%). No new safety concerns were reported.
Clinical Implications
Eric Hughes, MD, PhD, Executive Vice President of Global R&D and Chief Medical Officer at Teva, described the NDA submission as an important milestone for both the company and patients living with Tourette syndrome. He noted that the filing reflects progress within Teva’s innovative pipeline following the acquisition of the asset and supports the company’s broader growth strategy focused on differentiated medicines.
Path Forward
The FDA will now review the application and determine whether ecopipam should become a new treatment option for pediatric Tourette syndrome. A potential approval would provide physicians with a first-in-class therapy targeting dopamine D1 receptors and expand treatment choices for children and adolescents whose symptoms remain inadequately controlled with current medications.
Given its Fast Track and Orphan Drug status, ecopipam may benefit from an expedited regulatory review process. The FDA is expected to announce acceptance of the NDA and provide a review timeline in the coming months.
What This Means for Patients
Children and adolescents with Tourette syndrome have seen few new treatment options in recent years. If approved, ecopipam could become the first new FDA-approved therapy for pediatric Tourette syndrome in more than a decade and the first to target dopamine D1 receptors. Phase 3 data showed the drug significantly reduced the risk of symptom relapse compared with placebo and was generally well tolerated, potentially offering families an additional treatment option for managing motor and vocal tics.
Reference
About the Writer
Umesh Hanumante (M.Pharm) (LinkedIn) is a pharmacy professional and healthcare writer with a background in Regulatory Affairs, pharmaceutical innovation, and clinical research. He has around two years of industry experience as an Executive PMT at Troikaa Pharmaceuticals Ltd and qualified GPAT 2024. His areas of interest include regulatory compliance, dossier preparation, clinical trials, emerging therapies, and advancements in the global pharmaceutical and healthcare sector.